KCA 098

Drug Profile

KCA 098

Latest Information Update: 12 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Class Calcium regulators; Coumarins; Isoflavones; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Postmenopausal osteoporosis

Most Recent Events

  • 21 Jan 2000 Preclinical development for Postmenopausal osteoporosis in Japan (PO)
  • 21 Jan 2000 A preclinical study has been added to the pharmacokinetics section
  • 19 Oct 1995 Discontinued-Preclinical for Postmenopausal osteoporosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top